Reliable expression, analytics and supply for confident development decisions.
Explore capabilities ↓Build a programme around the biology, then draw on exactly the capabilities it needs. Our teams share context, materials and scientific intent from one stage to the next.
We offer a seamless workflow from expression to characterization:
Rapid production of antibodies in HEK293 or CHO systems—ideal for early-stage screening and functional assays.
Generation of high-yield, clonally stable lines for long-term supply and scale-up.
Comprehensive profiling including titer, purity, aggregation, binding kinetics, functional activity, immunogenicity and epitope mapping.
Whether you're validating hits or preparing for IND-enabling studies, we deliver:
Why Choose Fusion?
| What We Offer | Why It Matters |
|---|---|
| Flexible Expression Systems | Transient expression suits short timelines and small-scale needs, while stable cell lines enable long-term, large-scale production. |
| Sequence Liability Screening | Early alerts for major sequence liabilities—before production begins |
| Quality-Assured Cell Culture | Antibodies are produced in actively growing, well-maintained cells—ensuring correct folding and authentic post-translational modifications |
| High-Yield Production | Proprietary plasmid design and optimized protocol for high production yield |
| Optimized Purification Workflow | Multiple purification strategies ensure consistently high-purity antibody products. |
| In-house analytical capabilities | Comprehensive QC to confirm product integrity and performance |
Fusion’s antibody supply services are built to support your pipeline from discovery through development. Whether you're advancing a novel therapeutic or validating a lead candidate, we ensure the antibodies you receive are consistent, functional, and ready for the next step.
Let’s accelerate your research with high-quality antibodies you can trust.
connected capabilities
Polyclonal antibodies play a vital role in both research and clinical applications due to their ability to recognise multiple epitopes on a single antigen. This multi-epitope recognition enhances their sensitivity and makes them particularly effective in detecting low-abundance targets, even in complex biological samples.
In the race to engineer high-affinity, highly selective antibodies, understanding the precise interaction between antibody and antigen is no longer a luxury—it’s a necessity. Epitope mapping using cross-linking mass spectrometry (XL-MS) offers a powerful, high-resolution approach to define these critical interfaces with speed and confidence.
Fusion Antibodies provides a robust portfolio of antibody characterisation services designed to generate high-quality data that supports confident decision-making across discovery, development, and translation. Our services are available as stand-alone studies or fully integrated with antibody generation, engineering, and reformatting programmes.
At Fusion Antibodies, we bring extensive experience with a variety of mammalian expression systems to support your clinical development with confidence and flexibility. We specialize in the rapid generation of well-characterized, regulatory-compliant cell lines with strong clinical track records.
Fusion Antibodies delivers expert mammalian transient gene expression (TGE) for rapid, scalable protein generation. Our platform supports assay development, antibody screening, structural biology, and preclinical studies—with speed, precision, and reproducibility.
Reliable expression, analytics and supply for confident development decisions.
Reliable expression, analytics and supply for confident development decisions.
When programmes move between disconnected providers, knowledge is diluted. At Fusion, the same scientific context can travel from target and lead generation through engineering, characterisation and supply.
Bring us a target, an existing antibody or a difficult development decision.
Start a conversation →